{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:05:59Z","timestamp":1786993559970,"version":"build-2736575974"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jtos.2022.08.004","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T22:04:03Z","timestamp":1660341843000},"page":"191-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-0752","authenticated-orcid":false,"given":"Andrew","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Asbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtos.2022.08.004_bib1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/all.13786","article-title":"Management of ocular allergy","volume":"74","author":"Leonardi","year":"2019","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000299","article-title":"An update on ocular allergy","volume":"16","author":"Shaker","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ACI.0b013e32830edbcb","article-title":"Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models","volume":"8","author":"Niederkorn","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clae.2008.07.003","article-title":"The pathophysiology of ocular allergy: a review","volume":"32","author":"Chigbu","year":"2009","journal-title":"Contact Lens Anterior Eye"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ACI.0b013e3282ef8674","article-title":"Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities","volume":"7","author":"Leonardi","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000437424","article-title":"Involvement of chemokines and a CD4-positive T cell subset in the development of conjunctival secondary lymphoid follicles in an atopic keratoconjunctivitis mouse model","volume":"167","author":"Shoji","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1350-9462(02)00006-X","article-title":"Vernal keratoconjunctivitis: pathogenesis and treatment","volume":"21","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"issue":"Suppl 1","key":"10.1016\/j.jtos.2022.08.004_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.2008.03716.x","article-title":"Allergy and the eye","volume":"153","author":"Leonardi","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtos.2022.08.004_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtos.2020.09.009","article-title":"Conjunctival transcriptome analysis reveals the overexpression of multiple pattern recognition receptors in vernal keratoconjunctivitis","volume":"19","author":"Leonardi","year":"2021","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib10","first-page":"76","article-title":"Immunopathology of allergic conjunctivitis","volume":"3","author":"Chigbu","year":"2018","journal-title":"Eng Manag J"},{"key":"10.1016\/j.jtos.2022.08.004_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.survophthal.2018.12.001","article-title":"Vernal keratoconjunctivitis","volume":"64","author":"Singhal","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jtos.2022.08.004_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jtos.2021.08.009","article-title":"Kitaura Pollen shells and soluble factors play non-redundant roles in the development of allergic conjunctivitis in mice","volume":"22","author":"Fukase","year":"2021","journal-title":"J.Ocul Surf."},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/ACI.0b013e328357a21b","article-title":"Molecular immunology of allergic conjunctivitis","volume":"12","author":"Irkec","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2022.08.004_bib15","first-page":"932","article-title":"Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis","volume":"17","author":"Wakamatsu","year":"2011","journal-title":"Mol Vis"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/08820538.2016.1238097","article-title":"Clinical severity and tear biomarkers, eosinophil cationic protein and CCL23, in chronic allergic conjunctival diseases","volume":"33","author":"Shoji","year":"2018","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/02713683.2016.1242755","article-title":"Clinical usefulness of simultaneous measurement of the tear levels of CCL17, CCL24, and IL-16 for the biomarkers of allergic conjunctival disorders","volume":"42","author":"Shoji","year":"2017","journal-title":"Curr Eye Res"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138945006775270204","article-title":"Asthma, allergy and chemokines","volume":"7","author":"Pease","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.004_bib19","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1398-9995.2004.00710.x","article-title":"Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases","volume":"59","author":"Elsner","year":"2004","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1385\/IR:33:3:213","article-title":"A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva","volume":"33","author":"Nakamura","year":"2005","journal-title":"Immunol Res"},{"issue":"2","key":"10.1016\/j.jtos.2022.08.004_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxn137","article-title":"Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1\/CCR3 blockade","volume":"21","author":"Miyazaki","year":"2009","journal-title":"Int Immunol"},{"issue":"8","key":"10.1016\/j.jtos.2022.08.004_bib22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/bjophthalmol-2011-301399","article-title":"The murine CCR3 receptor regulates both eosinophilia and hyperresponsiveness in IgE-mediated allergic conjunctivitis","volume":"96","author":"Fukuda","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.004_bib23","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1167\/iovs.08-2154","article-title":"Transcriptional analyses before and after suppression of immediate hypersensitivity reactions by CCR3 blockade in eyes with experimental allergic conjunctivitis","volume":"49","author":"Komatsu","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7252","key":"10.1016\/j.jtos.2022.08.004_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature08151","article-title":"CCR3 is a target for age-related macular degeneration diagnosis and therapy","volume":"460","author":"Takeda","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jtos.2022.08.004_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108076","article-title":"Analysis of CCR3 expression in corneal neovascularization in a murine model and human corneas","volume":"197","author":"Haber","year":"2020","journal-title":"Exp Eye Res"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.004_bib26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/bjophthalmol-2014-305425","article-title":"Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts","volume":"98","author":"Fukuda","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.08.004_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/2045-7022-4-40","article-title":"Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops","volume":"4","author":"Ueta","year":"2014","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2332\/allergolint.13-OA-0605","article-title":"Usefulness of a new therapy using rebamipide eyedrops in patients with VKC\/AKC refractory to conventional anti-allergic treatments","volume":"63","author":"Ueta","year":"2014","journal-title":"Allergol Int"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.004_bib29","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/all.12042","article-title":"The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial","volume":"67","author":"Horak","year":"2012","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.004_bib30","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","article-title":"Targeting the PGD2\/CRTH2\/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives","volume":"77","author":"Kupczyk","year":"2017","journal-title":"Drugs"},{"issue":"8 Suppl","key":"10.1016\/j.jtos.2022.08.004_bib31","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/01.ico.0000178733.42921.4c","article-title":"Prostaglandin D2 induces chemotaxis in eosinophils via its receptor CRTH2 and eosinophils may cause severe ocular inflammation in patients with allergic conjunctivitis","volume":"24","author":"Fujishima","year":"2005","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.004_bib32","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","article-title":"Targeting the PGD 2\/CRTH2\/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives","volume":"77","author":"Kupczyk","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jtos.2022.08.004_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13223-017-0183-z","article-title":"Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies","volume":"13","author":"Ratner","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"11","key":"10.1016\/j.jtos.2022.08.004_bib34","doi-asserted-by":"crossref","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","article-title":"Galectin-1: a small protein with major functions","volume":"16","author":"Camby","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.jtos.2022.08.004_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1749-6632.2011.06386.x","article-title":"Galectins in acute and chronic inflammation","volume":"1253","author":"Liu","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.jtos.2022.08.004_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1167\/iovs.14-15100","article-title":"Immunomodulatory effects of galectin-1 on an IgE-mediated allergic conjunctivitis model","volume":"56","author":"Mello","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"33","key":"10.1016\/j.jtos.2022.08.004_bib37","doi-asserted-by":"crossref","first-page":"E4837","DOI":"10.1073\/pnas.1601958113","article-title":"Regulation of eosinophilia and allergic airway inflammation by the glycan-binding protein galectin-1","volume":"113","author":"Ge","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.004_bib38","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.4049\/jimmunol.1203501","article-title":"Galectin-1-mediated suppression of Pseudomonas aeruginosa-induced corneal immunopathology","volume":"190","author":"Suryawanshi","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jtos.2022.08.004_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2018.05.046","article-title":"Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis","volume":"833","author":"Mello-Bosnic","year":"2018","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.jtos.2022.08.004_bib40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1081-1206(10)63170-5","article-title":"Expression of ICAM-1 on conjunctival epithelium and ECP in tears and serum from children with allergic conjunctivitis","volume":"82","author":"Oh","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jtos.2022.08.004_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fphar.2012.00203","article-title":"Therapeutic targeting of eosinophil adhesion and accumulation in allergic conjunctivitis","volume":"3","author":"Baiula","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtos.2022.08.004_bib43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fchem.2019.00489","article-title":"Novel ligands targeting \u03b14\u03b21 integrin: therapeutic applications and perspectives","volume":"7","author":"Baiula","year":"2019","journal-title":"Front Chem"},{"key":"10.1016\/j.jtos.2022.08.004_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jtos.2021.03.009","article-title":"Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1\/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model","volume":"21","author":"Singh","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.08.004_bib45","first-page":"310","article-title":"Role of VLA-4 in the development of allergic conjunctivitis in mice","volume":"12","author":"Fukushima","year":"2006","journal-title":"Mol Vis"},{"issue":"10","key":"10.1016\/j.jtos.2022.08.004_bib46","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1164\/rccm.200207-696OC","article-title":"A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation","volume":"167","author":"Koo","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jtos.2022.08.004_bib47","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jaci.2005.07.003","article-title":"Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1-dependent functions","volume":"116","author":"Sedgwick","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jtos.2022.08.004_bib48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/sj.bjp.0706658","article-title":"A small molecule, orally active, alpha4beta1\/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats","volume":"147","author":"Cortijo","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jtos.2022.08.004_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00063030-200822020-00002","article-title":"Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease","volume":"22","author":"Woodside","year":"2008","journal-title":"BioDrugs"},{"issue":"20","key":"10.1016\/j.jtos.2022.08.004_bib50","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1111\/bph.14458","article-title":"DS-70, a novel and potent \u03b14 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in Guinea pigs","volume":"175","author":"Dattoli","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1165\/rcmb.2002-0311OC","article-title":"Regulation of bone marrow and airway CD34+ eosinophils by interleukin-5","volume":"30","author":"Sitkauskiene","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib52","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2222.2011.03854.x","article-title":"Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor","volume":"42","author":"Molfino","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1081\/JAS-200063001","article-title":"Eosinophils from asthmatics release IL-5 in an autocrine fashion to prevent apoptosis through upregulation of Bcl-2 expression","volume":"42","author":"Huang","year":"2005","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2249.1997.d01-884.x","article-title":"IL-5 but not interferon-gamma (IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression","volume":"107","author":"Ochiai","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.jtos.2022.08.004_bib55","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.jtos.2022.08.004_bib56","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1164\/rccm.202003-0729LE","article-title":"Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma","volume":"202","author":"Moran","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.jtos.2022.08.004_bib58","first-page":"649","article-title":"Biologics for the treatment of allergic conditions: eosinophil disorders","volume":"40","author":"Olivieri","year":"2020","journal-title":"Immunol Allergy Clin"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1398-9995.2008.01881.x","article-title":"Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment","volume":"64","author":"van Rensen","year":"2009","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.jtos.2022.08.004_bib60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/biomedicines9070787","article-title":"Omalizumab restores response to corticosteroids in patients with eosinophilic chronic rhinosinusitis and severe asthma","volume":"9","author":"Kobayashi","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaapos.2012.12.153","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"de Klerk","year":"2013","journal-title":"J AAPOS"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.aller.2011.08.002","article-title":"Omalizumab. An option in vernal keratoconjunctivitis?","volume":"40","author":"S\u00e1nchez","year":"2012","journal-title":"Allergol Immunopathol"},{"issue":"2","key":"10.1016\/j.jtos.2022.08.004_bib63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.29262\/ram.v65i2.292","article-title":"Eficacia a largo plazo del omalizumab en pacientes con queratoconjuntivitis vernal resistente a tratamiento convencional [Long-term efficacy of omalizumab in patients with conventional treatment-resistant vernal keratoconjunctivitis]","volume":"65","author":"Santamar\u00eda","year":"2018","journal-title":"Rev Alerg Mex"},{"issue":"5","key":"10.1016\/j.jtos.2022.08.004_bib64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/pai.12737","article-title":"Vernal keratoconjunctivitis treated with omalizumab: a case series","volume":"28","author":"Occasi","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"10.1016\/j.jtos.2022.08.004_bib65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","article-title":"Omalizumab treatment of vernal keratoconjunctivitis","volume":"134","author":"Heffler","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40123-016-0074-2","article-title":"Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature","volume":"6","author":"Doan","year":"2017","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.004_bib67","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.intimp.2008.10.021","article-title":"Quercetin regulates Th1\/Th2 balance in a murine model of asthma","volume":"9","author":"Park","year":"2009","journal-title":"Int Immunopharm"},{"issue":"6","key":"10.1016\/j.jtos.2022.08.004_bib68","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12272-001-1225-2","article-title":"Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious Guinea-pigs","volume":"31","author":"Moon","year":"2008","journal-title":"Arch Pharm Res (Seoul)"},{"key":"10.1016\/j.jtos.2022.08.004_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110924","article-title":"Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis [published correction appears in Food Chem Toxicol","volume":"135","author":"Ding","year":"2020","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib70","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13052-019-0678-y","article-title":"A polycentric, randomized, parallel-group, study on Lertal\u00ae, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: phase II","volume":"45","author":"Marseglia","year":"2019","journal-title":"Ital J Pediatr"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cells10010019","article-title":"Discovery, function, and therapeutic targeting of siglec-8","volume":"10","author":"Youngblood","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jtos.2022.08.004_bib72","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1074\/jbc.275.2.861","article-title":"Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily","volume":"275","author":"Floyd","year":"2000","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.jtos.2022.08.004_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.jtos.2022.08.004_bib74","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10875-011-9589-4","article-title":"Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression","volume":"31","author":"Hudson","year":"2011","journal-title":"J Clin Immunol"},{"issue":"6","key":"10.1016\/j.jtos.2022.08.004_bib75","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.jaci.2018.10.066","article-title":"Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: receptor expression and targeting using chimeric antibodies","volume":"143","author":"Legrand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jtos.2022.08.004_bib76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000488951","article-title":"Characterization of siglec-8 expression on lavage cells after segmental lung allergen challenge","volume":"177","author":"Johansson","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jtos.2022.08.004_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.12.950","article-title":"A randomized, double-bind, placebo-controlled, ascending dose phase 1 study of AK002, a novel siglec-8 selective monoclonal antibody, in health subjects","volume":"141","author":"Rasmussen","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"10.1016\/j.jtos.2022.08.004_bib78","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtos.2022.08.004_bib79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11894-021-00809-2","article-title":"Eosinophilic gastritis\/gastroenteritis","volume":"23","author":"Chen","year":"2021","journal-title":"Curr Gastroenterol Rep"},{"issue":"21","key":"10.1016\/j.jtos.2022.08.004_bib80","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria [published online ahead of print, 2021 Dec 23]","volume":"S0091\u20136749","author":"Altrichter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"S106","key":"10.1016\/j.jtos.2022.08.004_bib81","article-title":"LBTP1937: safety and efficacy data of AK002, an anti-siglec-8 monoclonal antibody, in patients with indolent systemic mastocytosis (ISM): results from a first-in-human, open-label phase 1 study","volume":"74","author":"Siebenhaar","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2022.08.004_bib82","doi-asserted-by":"crossref","first-page":"AB185","DOI":"10.1016\/j.jaci.2019.12.323","article-title":"Phase 1b study of AK002, an anti-siglec-8 monoclonal antibody, in patients with severe allergic conjunctivitis (KRONOS study)","volume":"145","author":"Levine","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422000763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422000763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:50:22Z","timestamp":1761540622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012422000763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":82,"alternative-id":["S1542012422000763"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2022.08.004","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2022.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}